SCHEMBL6287006

SCHEMBL6287006

COc1ccc(-c2nn3c(C)nc(C)c3c(=O)[nH]2)cc1OC

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 2/20 0.53
PDE1A P54750 2/20 0.53
PDE1B Q01064 2/20 0.53
PDE1C Q14123 2/20 0.53
GUSB P08236 1/20 0.50
KDM4E B2RXH2 3/20 0.45
ALDH1A1 P00352 2/20 0.45
MEN1 O00255 1/20 0.45
POLB P06746 1/20 0.45
MAPT P10636 1/20 0.45
HPGD P15428 1/20 0.45
KMT2A Q03164 1/20 0.45
MAPK1 P28482 1/20 0.45
ALOX5 P09917 1/20 0.43
EPHX2 P34913 1/20 0.43
CCNE2 O96020 1/20 0.42
CCNE1 P24864 1/20 0.42
CDK2 P24941 1/20 0.42
PARP1 P09874 1/20 0.42
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6288690 0.90 PDE5A (0.50) PDE5APDE1APDE1BPDE1CGUSB
SCHEMBL6291723 0.86 CCNE2 (0.51) PDE5APDE1APDE1BPDE1CGUSB
SCHEMBL6291287 0.86 PDE2A (0.47) GUSBKDM4EALDH1A1MEN1POLB
SCHEMBL6288434 0.85 KDM4E (0.48) GUSBKDM4EALDH1A1MAPTHPGD
SCHEMBL6291850 0.84 PDE5A (0.53) PDE5APDE1APDE1BPDE1CGUSB
SCHEMBL6291830 0.83 PDE2A (0.45) PDE5APDE1APDE1BPDE1CGUSB
SCHEMBL6291835 0.82 PDE5A (0.59) PDE5APDE1APDE1BPDE1CGUSB
SCHEMBL6288598 0.82 PDE2A (0.46) PDE5APDE1APDE1BPDE1CGUSB
SCHEMBL6291810 0.81 PDE5A (0.50) PDE5APDE1APDE1BPDE1CALDH1A1
SCHEMBL5916454 0.80 PDE2A (0.56) PDE5APDE1APDE1BPDE1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6936609-B2 Imidazotriazines for use as phosphodiesterase inhibitors BAYER HEALTHCARE AG (DE) 2005-08-30 US disclosed
US-20040249148-A1 Imidazotriazines for use as phosphodiesterase inhibitors BAYER HEALTHCARE AG (DE) 2004-12-09 US disclosed
EP-1404677-A1 IMIDAZOTRIAZINES FOR USE AS PHOSPHODIESTERASE INHIBITORS Bayer HealthCare AG (DE) 2004-04-07 EP disclosed
WO-2003000693-A1 IMIDAZOTRIAZINES FOR USE AS PHOSPHODIESTERASE INHIBITORS BAYER HEALTHCARE AG (DE) 2003-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040249148-A1 Imidazotriazines for use as phosphodiesterase inhibitors PDE3A, PDE2A, PDE4A PDE5A 4/4885PDE1A 8/4885PDE1B 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.